a public good project by the
Synthesis
Company
of California

© 2026

Judith Straimer | doi.page

0 works0 citations0 h-index

Judith Straimer

Novartis (China)(CN)Novartis (United States)(US)NovaBay Pharmaceuticals (United States)(US)

Publications by Year

Research Areas

Malaria Research and Control, Computational Drug Discovery Methods, Mosquito-borne diseases and control, Research on Leishmaniasis Studies, Trypanosoma species research and implications

Most-Cited Works

→ K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates(2014)735 cited
→ A Worldwide Map ofPlasmodium falciparumK13-Propeller Polymorphisms(2016)567 cited
→ Artemisinin Action and Resistance in Plasmodium falciparum(2016)355 cited
→ Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies(2016)343 cited
→ Targeting the Cell Stress Response of Plasmodium falciparum to Overcome Artemisinin Resistance(2015)339 cited
→ Plasmodium falciparum K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness(2021)170 cited
→

Site-specific genome editing in Plasmodium falciparum using engineered zinc-finger nucleases

(2012)

167 cited

→ Plasmodium falciparum K13 Mutations Differentially Impact Ozonide Susceptibility and Parasite Fitness In Vitro(2017)134 cited

→ High Prevalence of Plasmodium falciparum K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance After Treatment With Artemether-Lumefantrine(2021)121 cited

→ Insights into the intracellular localization, protein associations and artemisinin resistance properties of Plasmodium falciparum K13(2020)85 cited